Mỹ phê duyệt thuốc viên Molnupiravir điều trị COVID-19 tại nhà

Thế giới

Cơ quan quản lý dược phẩm và thực phẩm Mỹ ngày 23/12 đã phê duyệt thuốc viên kháng virus của Merck & Co, dùng trong điều trị COVID-19, có tên Molnupiravir.

Email Print twitter facebook

08:20 24/12/2021 GMT+7

Đọc nhiều

{publishtime}

{title}
{publishtime}
{title}
{lead}

{title}

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

(TTXVN/Vietnam+)

{name} - {time}

Trả lời

{body}

{name} - {time}

{body}